Silverback Asset Management LLC Avadel Pharmaceuticals PLC Call Options Transaction History

Silverback Asset Management LLC

  • $47.9 Million
  • Q3 2024

Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Feb 13, 2024
BUY
$9.64 - $14.59 $964,000 - $1.46 Million
100,000 New
100,000 $1.41 Million
Q1 2023

May 15, 2023
SELL
$6.41 - $9.95 $174,352 - $270,640
-27,200 Reduced 7.24%
348,600 $3.19 Million
Q4 2022

Feb 14, 2023
BUY
$5.02 - $10.0 $380,515 - $758,000
75,800 Added 25.27%
375,800 $2.69 Million
Q3 2022

Mar 02, 2023
SELL
$2.57 - $7.31 $194,806 - $554,098
-75,800 Reduced 20.17%
300,000 $1.45 Million
Q3 2022

Nov 14, 2022
BUY
$2.57 - $7.31 $771,000 - $2.19 Million
300,000 New
300,000 $1.5 Million

Others Institutions Holding AVDL

# of Institutions
8
Shares Held
1.07M
Call Options Held
0
Put Options Held
0
View Full List

About AVADEL PHARMACEUTICALS PLC

AVDL Quotes by TradingView
  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $650M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Silverback Asset Management LLC Portfolio

Follow Silverback Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silverback Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silverback Asset Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email